Sökresultat - Daniel J. DeAngelo

Förfina resultatet
  1. 1
    Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia

    Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia av Shai Shimony, Daniel J. DeAngelo, Marlise R. Luskin

    Publicerad 2023
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  2. 2
    New Approaches to the Management of Adult Acute Lymphoblastic Leukemia

    New Approaches to the Management of Adult Acute Lymphoblastic Leukemia av Renato Bassan, Jean‐Pierre Bourquin, Daniel J. DeAngelo, Sabina Chiaretti

    Publicerad 2018
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  3. 3
    Novel <i>SSBP2‐JAK2</i> fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre‐B acute lymphocytic leukemia

    Novel <i>SSBP2‐JAK2</i> fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre‐B acute lymphocytic leukemia av Jennifer L. Poitras, Paola Dal Cin, Jon C. Aster, Daniel J. DeAngelo, Cynthia C. Morton

    Publicerad 2008
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  4. 4
    Invasive fungal disease in patients treated for newly diagnosed acute leukemia

    Invasive fungal disease in patients treated for newly diagnosed acute leukemia av Sarah P. Hammond, Francisco M. Marty, Julie M. Bryar, Daniel J. DeAngelo, Lindsey R. Baden

    Publicerad 2010
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  5. 5
    Gefitinib induces myeloid differentiation of acute myeloid leukemia

    Gefitinib induces myeloid differentiation of acute myeloid leukemia av Kimberly Stegmaier, Steven M. Corsello, Kenneth N. Ross, Jenny Wong, Daniel J. DeAngelo, Todd R. Golub

    Publicerad 2005
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  6. 6
    SYK regulates mTOR signaling in AML

    SYK regulates mTOR signaling in AML av Julia Carnevale, Linda Ross, Alexandre Puissant, Versha Banerji, Richard M. Stone, Daniel J. DeAngelo, Kenneth N. Ross, Kimberly Stegmaier

    Publicerad 2013
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  7. 7
    Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

    Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review av Jorge E. Cortés, Jane F. Apperley, Daniel J. DeAngelo, Michael W. Deininger, Vamsi Kota, Philippe Rousselot, Carlo Gambacorti‐Passerini

    Publicerad 2018
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  8. 8
    The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consortium protocols

    The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consorti... av Rachael F. Grace, Suzanne E. Dahlberg, Donna Neuberg, Stephen E. Sallan, Jean M. Connors, Ellis J. Neufeld, Daniel J. DeAngelo, Lewis B. Silverman

    Publicerad 2011
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  9. 9
    Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome

    Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome av Edwin P. Alyea, Haesook T. Kim, Vincent T. Ho, Corey Cutler, Daniel J. DeAngelo, Richard M. Stone, Jerome Ritz, Joseph H. Antin, Robert J. Soiffer

    Publicerad 2006
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  10. 10
    A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

    A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia av Aaron D. Schimmer, Azra Raza, Thomas H. Carter, David F. Claxton, Harry P. Erba, Daniel J. DeAngelo, Martin S. Tallman, Carolyn A. Goard, Gautam Borthakur

    Publicerad 2014
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  11. 11
    Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

    Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML av Thanh‐Trang Vo, Jeremy Ryan, Ruben D. Carrasco, Donna Neuberg, Derrick J. Rossi, Richard M. Stone, Daniel J. DeAngelo, Mark G. Frattini, Anthony Letai

    Publicerad 2012
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  12. 12
    Clinical use of measurable residual disease in adult ALL: recommendations from a panel of U.S. experts

    Clinical use of measurable residual disease in adult ALL: recommendations from a panel of U.S. experts av Nicholas J. Short, Ibrahim Aldoss, Daniel J. DeAngelo, Marina Konopleva, Jessica T. Leonard, Aaron C. Logan, Jae H. Park, Bijal Shah, Wendy Stock, Elias Jabbour

    Publicerad 2025
    Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  13. 13
    Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes

    Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes av Alexander E. Sherman, Gabriela Motyckova, K. Rebecca Fega, Daniel J. DeAngelo, Gregory A. Abel, David P. Steensma, Martha Wadleigh, Richard M. Stone, Jane A. Driver

    Publicerad 2013
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  14. 14
    Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation

    Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation av Philippe Armand, Haesook T. Kim, Daniel J. DeAngelo, Vincent T. Ho, Corey Cutler, Richard M. Stone, Jerome Ritz, Edwin P. Alyea, Joseph H. Antin, Robert J. Soiffer

    Publicerad 2007
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  15. 15
    A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

    A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535) av Jeffrey E. Lancet, Anna Moseley, Steven Coutré, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum

    Publicerad 2020
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  16. 16
    Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients

    Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients av Shai Shimony, Jacqueline S. Garcia, Julia Keating, Evan C. Chen, Marlise R. Luskin, Maximilian Stahl, Donna Neuberg, Daniel J. DeAngelo, Richard M. Stone, R. Coleman Lindsley

    Publicerad 2024
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  17. 17
    Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

    Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 198... av Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven Coutré, Richard M. Stone, Alison Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson

    Publicerad 2007
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  18. 18
    Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia

    Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia av Patrick Bhola, Brenton G. Mar, R. Coleman Lindsley, Jeremy Ryan, Leah J. Hogdal, Thanh Trang Vo, Daniel J. DeAngelo, Ilene Galinsky, Benjamin L. Ebert, Anthony Letai

    Publicerad 2016
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  19. 19
    A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

    A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Synd... av Amer M. Zeidan, Daniel J. DeAngelo, Jeanne Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei, Ying Fei Li, Nanette Hock, Michael R. Burgess, Kristen Hege, Wendy Stock

    Publicerad 2019
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  20. 20
    Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema

    Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema av Matthew Torre, Isaac H. Solomon, Claire L. Sutherland, Sarah Nikiforow, Daniel J. DeAngelo, Richard M. Stone, Henrikas Vaitkevicius, Ilene Galinsky, Robert F. Padera, Nikolaus S. Trede, Sandro Santagata

    Publicerad 2018
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:

Sökverktyg: